1. Alessi P, Leali D, Camozzi M, Cantelmo A, Albini A, Presta M (2009) Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel anti-angiogenic FGF2-antagonists. Eur Cytokine Netw 20:225–234
2. Bałan BJ, Skopińska-Różewska E, Barcz E, Sokolnicka I, Gawrychowski K, Strzelecka H (1999) The effect of selected phenolic acids in angiogenic activity of ovarian cancer cells. Onkol Pol 4:203–208. (Article in Polish)
3. Barcz E, Sommer E, Sokolnicka I, Gawrychowski K, Roszkowska-Purska K, Janik P, Skopińska-Różewska E (1998) The influence of theobromine on angiogenic activity and proangiogenic cytokines production of human ovarian cancers cells. Oncol Rep 5:517–520
4. Barcz E, Sommer E, Janik P, Marianowski L, Skopińska-Różewska E (2000) Adenosine receptor antagonism causes inhibition of angiogenic activity of human ovarian cancer cells. Oncol Rep 7:1285–1291
5. Beaumont JL, Salsman JM, Diaz J, Deen KC, McCann L, Powles T, Hackshaw MD, Motzer RJ, Cella D (2016) Quality-adjusted time without symptoms or toxicity analysis of pzopanib vesrsus sunitynib in patients with renal cell carcinoma. Cancer 122:1108–1115